首页> 外文期刊>International Journal of Hematology >Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase
【24h】

Acute myeloid leukemia with mediastinal myeloid sarcoma refractory to acute myeloid leukemia therapy but responsive to l-asparaginase

机译:急性髓性白血病合并纵隔性髓样肉瘤,对急性髓样白血病治疗无效,但对L-天冬酰胺酶有反应

获取原文
获取原文并翻译 | 示例
       

摘要

We report the case of a 14-year-old female with acute myeloid leukemia (AML) and myeloid sarcomas (MS) in the anterior mediastinum and around numerous bones. Laboratory tests showed a white blood cell count of 4.0 × 109/l with 7.0 % blasts. Computed tomography revealed a mediastinal mass and pleural effusion; pleural effusion cytology was negative for malignant cells. In addition, disseminated intravascular coagulation (DIC) was present. Following DIC therapy, thoracoscopic and bone marrow biopsies were performed. Immunostaining and surface marker analysis revealed that the blast cells were positive for cytoplasmic myeloperoxidase, CD4, CD7, CD33, CD44, CD117, and HLA-DR, but negative for CD34 and CD56. Karyotype was normal. MS associated with AML was diagnosed. Multidrug chemotherapy for AML was completely ineffective, and MS continued to progress. Immunohistochemistry revealed that the blasts were negative for asparagine synthetase (AS); therefore, chemotherapy including l-asparaginase was initiated. After the first administration of l-asparaginase, the patient’s condition improved; however, she subsequently developed tumor lysis syndrome and sepsis, which eventually led to death. Aggressive MS in childhood is rare and refractory to existing AML chemotherapy. Chemotherapy including l-asparaginase may prove to be effective in such cases, especially those in which blast cells show negative AS expression.
机译:我们报道了一名14岁女性在前纵隔和众多骨骼周围患有急性髓样白血病(AML)和髓样肉瘤(MS)的病例。实验室测试显示,白细胞计数为4.0×109 / l,胚粒率为7.0%。计算机体层摄影显示纵隔肿块和胸腔积液。胸腔积液细胞学检查为恶性细胞阴性。另外,存在弥散性血管内凝血(DIC)。 DIC治疗后,进行胸腔镜和骨髓活检。免疫染色和表面标记分析表明,胚细胞对细胞质髓过氧化物酶,CD4,CD7,CD33,CD44,CD117和HLA-DR呈阳性,而对CD34和CD56呈阴性。核型正常。诊断出与AML相关的MS。 AML的多药化疗完全无效,并且MS仍在继续发展。免疫组织化学显示,胚芽细胞对天冬酰胺合成酶(AS)呈阴性。因此,开始了包括l-天冬酰胺酶的化学疗法。首次服用l-天冬酰胺酶后,患者的病情有所改善;然而,她随后发展为肿瘤溶解综合征和败血症,最终导致死亡。儿童期积极的MS很少见,并且对现有的AML化疗难以治疗。在这种情况下,包括l-天冬酰胺酶的化学疗法可能被证明是有效的,尤其是在原始细胞显示AS阴性表达的情况下。

著录项

  • 来源
    《International Journal of Hematology》 |2012年第1期|p.136-140|共5页
  • 作者单位

    Department of Hematology/Oncology, Saitama Children’s Medical Center, 2100 Magome, Iwatsuki-ku, Saitama, Saitama, 339-8551, Japan;

    Department of Hematology/Oncology, Saitama Children’s Medical Center, 2100 Magome, Iwatsuki-ku, Saitama, Saitama, 339-8551, Japan;

    Department of Hematology/Oncology, Saitama Children’s Medical Center, 2100 Magome, Iwatsuki-ku, Saitama, Saitama, 339-8551, Japan;

    Department of Pathology, Saitama Children’s Medical Center, Saitama, Japan;

    Department of Radiology, Saitama Children’s Medical Center, Saitama, Japan;

    Department of Hematology/Oncology, Saitama Children’s Medical Center, 2100 Magome, Iwatsuki-ku, Saitama, Saitama, 339-8551, Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Acute myeloid leukemia; Myeloid sarcoma; Mediastinal tumor; l-asparaginase; CD44;

    机译:急性髓性白血病;髓样肉瘤;纵隔肿瘤;l-天冬酰胺酶;CD44;
  • 入库时间 2022-08-17 23:58:24

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号